1. Home
  2. UBX vs LSTA Comparison

UBX vs LSTA Comparison

Compare UBX & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • UBX
  • LSTA
  • Stock Information
  • Founded
  • UBX 2009
  • LSTA 1980
  • Country
  • UBX United States
  • LSTA United States
  • Employees
  • UBX N/A
  • LSTA N/A
  • Industry
  • UBX Biotechnology: Pharmaceutical Preparations
  • LSTA Misc Health and Biotechnology Services
  • Sector
  • UBX Health Care
  • LSTA Health Care
  • Exchange
  • UBX Nasdaq
  • LSTA Nasdaq
  • Market Cap
  • UBX 38.6M
  • LSTA 31.2M
  • IPO Year
  • UBX 2018
  • LSTA N/A
  • Fundamental
  • Price
  • UBX $1.98
  • LSTA $2.62
  • Analyst Decision
  • UBX Strong Buy
  • LSTA Strong Buy
  • Analyst Count
  • UBX 2
  • LSTA 1
  • Target Price
  • UBX $7.00
  • LSTA $15.00
  • AVG Volume (30 Days)
  • UBX 335.8K
  • LSTA 60.0K
  • Earning Date
  • UBX 11-04-2024
  • LSTA 02-27-2025
  • Dividend Yield
  • UBX N/A
  • LSTA N/A
  • EPS Growth
  • UBX N/A
  • LSTA N/A
  • EPS
  • UBX N/A
  • LSTA N/A
  • Revenue
  • UBX N/A
  • LSTA N/A
  • Revenue This Year
  • UBX N/A
  • LSTA N/A
  • Revenue Next Year
  • UBX $33.62
  • LSTA N/A
  • P/E Ratio
  • UBX N/A
  • LSTA N/A
  • Revenue Growth
  • UBX N/A
  • LSTA N/A
  • 52 Week Low
  • UBX $0.94
  • LSTA $2.19
  • 52 Week High
  • UBX $3.10
  • LSTA $4.20
  • Technical
  • Relative Strength Index (RSI)
  • UBX 51.50
  • LSTA 43.38
  • Support Level
  • UBX $1.81
  • LSTA $2.51
  • Resistance Level
  • UBX $2.39
  • LSTA $2.66
  • Average True Range (ATR)
  • UBX 0.24
  • LSTA 0.20
  • MACD
  • UBX -0.06
  • LSTA -0.01
  • Stochastic Oscillator
  • UBX 26.56
  • LSTA 35.29

About UBX Unity Biotechnology Inc.

Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases. Its drug candidates include, UBX1325 is being developed for age-related diseases of the eye, including diabetic macular edema, or DME, UBX2089, which is a circulating hormone primarily produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications, and UBX2050.

About LSTA Lisata Therapeutics Inc.

Lisata Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Its product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively.

Share on Social Networks: